Paul Zuck
YOU?
Author Swipe
View article: <i>Ex vivo</i> and <i>in vivo</i> HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract
<i>Ex vivo</i> and <i>in vivo</i> HIV-1 latency reversal by “Mukungulu,” a protein kinase C-activating African medicinal plant extract Open
New HIV latency-reversing agents (LRAs) are needed that can reactivate and/or eliminate HIV reservoirs. “Mukungulu,” prepared from the plant Croton megalobotrys Müll Arg., is traditionally used for HIV/AIDS management in northern Botswana …
View article: An Immunocytochemistry Method to Investigate the Translationally Active HIV Reservoir
An Immunocytochemistry Method to Investigate the Translationally Active HIV Reservoir Open
Despite the success of combination antiretroviral therapy (cART) to suppress HIV replication, HIV persists in a long-lived reservoir that can give rise to rebounding viremia upon cART cessation. The translationally active reservoir consist…
View article: Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection
Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection Open
View article: Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo Open
Latency reversal strategies for HIV cure using inhibitor of apoptosis protein (IAP) antagonists (IAPi) induce unprecedented levels of latent reservoir expression without immunotoxicity during suppressive antiretroviral therapy (ART). Howev…
View article: Inferring HIV rebound timing from a noisy biomarker
Inferring HIV rebound timing from a noisy biomarker Open
View article: Initial productive and latent HIV infections originate in vivo by infection of resting T cells
Initial productive and latent HIV infections originate in vivo by infection of resting T cells Open
Productively infected cells are generally thought to arise from HIV infection of activated CD4+ T cells, and these infected activated cells are thought to be a recurring source of latently infected cells when a portion of the population tr…
View article: Productive and latent HIV infections originate in resting CD4<sup>+</sup>T cells
Productive and latent HIV infections originate in resting CD4<sup>+</sup>T cells Open
Summary Productively and latently HIV-infected cells are the source of virus that respectively establishes and sustains systemic infections and the reservoir in which HIV persists and rebounds when anti-retroviral therapy (ART) is interrup…
View article: Detecting Sources of Immune Activation and Viral Rebound in HIV Infection
Detecting Sources of Immune Activation and Viral Rebound in HIV Infection Open
Anti-retroviral therapy (ART) has greatly improved the quality and length of life for people living with HIV, but immune activation does not normalize during ART, and persistent immune activation has been linked to increased morbidity and …
View article: Detecting sources of immune activation and viral rebound in HIV infection
Detecting sources of immune activation and viral rebound in HIV infection Open
Antiretroviral therapy (ART) generally suppresses HIV replication to undetectable levels in peripheral blood, but immune activation associated with increased morbidity and mortality is sustained during ART, and infection rebounds when trea…
View article: Development of a fully automated platform for agar-based measurement of viable bacterial growth
Development of a fully automated platform for agar-based measurement of viable bacterial growth Open
Dynamic in vitro antibacterial studies provide valuable insight on effective dosing strategies prior to translating to in vivo models. Frequent sampling is required to monitor the pharmacodynamics (PD) of these studies, leading to signific…
View article: Neurotoxicity with high dose disulfiram and vorinostat used for HIV latency reversal
Neurotoxicity with high dose disulfiram and vorinostat used for HIV latency reversal Open
OBJECTIVE: To examine whether administering both vorinostat and disulfiram to people with HIV (PWH) on antiretroviral therapy (ART) is safe and can enhance HIV latency reversal. DESIGN: Vorinostat and disulfiram, can increase HIV transcrip…
View article: Improved Detection of HIV Gag p24 Protein Using a Combined Immunoprecipitation and Digital ELISA Method
Improved Detection of HIV Gag p24 Protein Using a Combined Immunoprecipitation and Digital ELISA Method Open
Greater than 90% of HIV-1 proviruses are thought to be defective and incapable of viral replication. While replication competent proviruses are of primary concern with respect to disease progression or transmission, studies have shown that…
View article: Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response
Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response Open
We demonstrate that human immunodeficiency virus (HIV) gag p24 protein is more readily detected in gut and lymph node tissues than in blood CD4+ T cells and correlates better with CD4 count during antiretroviral therapy (ART). Gut p24 leve…
View article: In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform Open
Antiretroviral therapy is able to effectively control but not eradicate HIV infection, which can persist, leading to the need for lifelong therapy. The existence of latently HIV-infected cells is a major barrier to the eradication of chron…
View article: Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy
Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy Open
Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using the intact proviral DNA assay (IPDA), along w…
View article: Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with histone deacetylase inhibitors (HDACi)
Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with histone deacetylase inhibitors (HDACi) Open
View article: Higher rectal p24 levels correlate with poor CD4 recovery in treated HIV infection
Higher rectal p24 levels correlate with poor CD4 recovery in treated HIV infection Open
View article: Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of <i>Mycobacterium tuberculosis</i> Dihydrofolate Reductase
Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of <i>Mycobacterium tuberculosis</i> Dihydrofolate Reductase Open
Though phenotypic and target-based high-throughput screening approaches have been employed to discover new antibiotics, the identification of promising therapeutic candidates remains challenging. Each approach provides different informatio…
View article: Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase
Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase Open
To combat the threat of antibiotic-resistant Gram-negative bacteria, novel agents that circumvent established resistance mechanisms are urgently needed. Our approach was to focus first on identifying bioactive small molecules followed by c…
View article: Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score
Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score Open
View article: High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators
High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators Open
Agonist shift assays feature cross-titrations of allosteric modulators and orthosteric ligands. Information generated in agonist shift assays can include a modulator's effect on the orthosteric agonist's potency (alpha) and efficacy (beta)…
View article: Dynamic Compound-Dependent Acoustic Transfer to Investigate Inhibitor Reversibility
Dynamic Compound-Dependent Acoustic Transfer to Investigate Inhibitor Reversibility Open
Automated mechanism of action studies are introducing the need for tailored compound delivery, which can be challenging for standard compound management procedures. Jump dilution assays investigating inhibitor reversibility require compoun…
View article: Development of a Platform to Enable Fully Automated Cross-Titration Experiments
Development of a Platform to Enable Fully Automated Cross-Titration Experiments Open
In the triage of hits from a high-throughput screening campaign or during the optimization of a lead compound, it is relatively routine to test compounds at multiple concentrations to determine potency and maximal effect. Additional follow…
View article: Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4
Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4 Open
View article: Screening of HIV-1 Protease Using a Combination of an Ultra-High-Throughput Fluorescent-Based Assay and RapidFire Mass Spectrometry
Screening of HIV-1 Protease Using a Combination of an Ultra-High-Throughput Fluorescent-Based Assay and RapidFire Mass Spectrometry Open